Patient Safety Risk
The Food and Drug Administration March 20 issued an alert on a potentially high-risk issue with Calyxo CVAC Aspiration Systems.
In this conversation, Carlos Roberts, M.D., urogynecologist, vice president and chief medical officer of the Women and Children service line at WellSpan Health, discusses the organization's commitment to zero harm, its innovative tier structure for daily safety huddles, and its fostered culture of…
In this “Safety Speaks” conversation, CommonSpirit Health's Beth Miller, system director, patient safety-performance improvement, and Austin Peterson, system director, patient harm prevention, discuss how safety transparency benefits both patients and providers, and how a CommonSpirit Health…
Explore transformative health care quality insights and the AHA Patient Safety Initiative, addressing challenges, trends and future priorities
The Food and Drug Administration Feb. 23 withdrew approval of Pepaxto (melphalan flufenamide), a drug once used with dexamethasone to treat certain U.S. patients with multiple myeloma, because a post-approval trial did not show it safe or effective.
In this podcast episode, listeners will learn how to create a culture of cybersecurity in their organization and facilitate board-level risk visibility and accountability to ultimately protect patient safety.
AHA submitted comments on how the Agency for Healthcare Research and Quality can best support the field in advancing patient safety through an action alliance, which the agency is launching in partnership with health care systems and patient safety advocates
Abbott has recalled certain Dragonfly OpStar imaging catheters because a marker band may remain in the patient after use.
AHA today urged the FTC to scrutinize commercial health plans that steer patients to third-party specialty pharmacies in which they have a financial interest.
FDA issues updates on a COVID-19 monoclonal antibody and antiviral pill, and certain Fresenius Medical Care hemodialysis machines.